This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dendreon
ClinicalTrials.gov Identifier:
NCT01487863
First received: December 6, 2011
Last updated: May 11, 2017
Last verified: May 2017
December 6, 2011
May 11, 2017
December 2011
May 2016   (Final data collection date for primary outcome measure)
Cumulative CD54 Upregulation Ratio Between the Cohorts. [ Time Frame: Over the course of sipuleucel-T therapy (approximately 1 month) ]
An analysis of variance model for the log transformed cumulative CD54 upregulation ratio (CD54 upregulation is the fold increase in the final product (FP) from buoyant density separations (BDS) step 65. BDS65 step refers to sample taken after both BDS77 and BDS65 but before ex vivo culture in the presence of antigen PA2024. FP refers to sample taken after ex vivo culture) that includes the antigen concentration cohort as the independent variable was performed. Subjects who received all 3 infusions were included.
Evaluate cumulative sipuleucel-T CD54 upregulation [ Time Frame: Over the course of sipuleucel-T therapy (approximately 1 month) ]
Complete list of historical versions of study NCT01487863 on ClinicalTrials.gov Archive Site
Not Provided
  • Evaluate sipuleucel-T product parameters [ Time Frame: Over the course of sipuleucel-T therapy (approximately 1 month) ]
    To evaluate sipuleucel-T product parameters of cumulative CD54+ cell count and total nucleated cell count
  • Evaluate the peripheral immune response to sipuleucel-T [ Time Frame: From baseline through 26 weeks ]
    Peripheral immune responses to sipuleucel-T will be measured, including IFN-gamma production by T cells, T cell proliferation, and antibody production (humoral response) to both PA2024 and PAP
  • Evaluate safety of sipuleucel-T therapy with concurrent or sequential administration of abiraterone acetate plus prednisone [ Time Frame: From registration to 30 days following the last study treatment ]
    Safety will be assessed by evaluation of adverse events, laboratory tests, vital signs, ECOG performance status, and physical examinations
Not Provided
Not Provided
 
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
The purpose of this study was to evaluate the impact of concurrent versus sequential administration of abiraterone acetate plus prednisone on the ability to manufacture sipuleucel-T (by assessing sipuleucel-T product parameters), and to assess the safety and efficacy of sipuleucel-T with concurrent or sequential administration of abiraterone acetate plus prednisone in men with metastatic castrate resistant prostate cancer.

Subjects underwent screening procedures at the Screening Visit to ensure that they met the inclusion and exclusion criteria outlined in the protocol. Subjects were evaluated for eligibility criteria, and if eligible, were registered and randomized in a 1:1 into either the Concurrent Arm or the Sequential Arm.

Subjects in both arms underwent a standard 1.5 to 2.0 blood volume leukapheresis, followed approximately 3 days later by an intravenous (IV) infusion of sipuleucel-T. This process occurred at approximately 2-week intervals. A course of sipuleucel-T treatment comprised three infusions.

Following the first infusion, subjects were limited to a maximum of three total product failures for all subsequent infusions, due specifically to insufficient total nucleated cell (TNC) count and/or CD54 upregulation. These subjects received no further leukaphereses or sipuleucel-T infusions, but did receive abiraterone acetate plus prednisone per the schedule of the arm to which they were randomized. All subjects received a total of 26 weeks of abiraterone acetate plus prednisone therapy.

All immune monitoring (IM) endpoints were collected from all subjects who received at least one infusion. Cellular and serological immune responses were assessed for subjects in both arms. In both arms, IM blood samples were collected at baseline (screening); pre-leukapheresis 2 and 3; post-infusion 1, 2, and 3; and weeks 6, 10, 14, and 26, with the timing of IM visits based on the onset of treatment (Day 0). Day 0 was the day of the first infusion. Post-infusion blood draws occurred at 3 hours (allowable window 1-24 hours) after each infusion. If a subject received only one or two infusions, immune samples were still drawn at the scheduled time points based on the first infusion (Day 0). If the subject was not scheduled to undergo further leukapheresis, no other pre-leukapheresis procedures were conducted.

During the active follow-up phase, subjects were followed from registration through the Post-Treatment Visit (30-37 days post-last study treatment), or until disease progression, unacceptable toxicity, or death, whichever occurred first.

During the long-term follow-up (LTFU) phase, subjects were followed from the Post-Treatment Visit for up to 3 years from the date of registration/randomization. During the LTFU phase, only new treatment-related serious adverse event (SAE)s, cerebrovascular event (CVE)s (regardless of causality), the first anti-cancer therapy and first chemotherapy, and survival status were collected via a quarterly telephone call.

Overall survival was measured as the time from randomization until death over a 3-year period.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Basic Science
  • Prostate Cancer Metastatic
  • Hormone Refractory Prostate Cancer
  • Castration-resistant Prostate Cancer
  • Biological: sipuleucel-T
    Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
    Other Names:
    • PROVENGE(R)
    • APC8015
  • Drug: abiraterone acetate
    Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
    Other Name: ZYTIGA(R)
  • Experimental: Concurrent Arm
    Subjects received sipuleucel-T concurrent with abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone treatment started the next day after the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
    Interventions:
    • Biological: sipuleucel-T
    • Drug: abiraterone acetate
  • Experimental: Sequential Arm
    Subjects received sipuleucel-T therapy followed by abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone started at week 10 from the start of the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
    Interventions:
    • Biological: sipuleucel-T
    • Drug: abiraterone acetate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
69
June 2016
May 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • histologically documented prostate cancer confirmed by a pathology report from prostate biopsy or radical prostatectomy specimen
  • metastatic status as evidenced by imaging obtained </= 56 days prior to registration demonstrating bone metastasis or lymph node metastasis
  • castrate resistant prostate cancer: castrate levels of testosterone (</= 50 ng/dL); evidence of disease progression concomitant with surgical or medical castration
  • serum PSA >/= 2.0 ng/mL
  • castrate levels of testosterone (</= 50 ng/dL) achieved via medical or surgical castration
  • baseline Eastern Cooperative Oncology Group (ECOG) performance status of </= 1
  • systolic blood pressure (BP) </= 140 mm Hg and diastolic BP </= 90 mm Hg at screening
  • adequate baseline hematologic, renal, and liver functions
  • must live in a permanent residence within a comfortable driving distance (round trip within one day) of the clinical trial site

Exclusion Criteria:

  • the presence of known lung, liver, or brain metastases, malignant pleural effusions, or malignant ascites
  • New York Heart Association Class III or IV heart failure
  • any medical condition that may be compromised by increases in blood pressure, hypokalemia, or fluid retention
  • Child-Pugh Class B or C hepatic insufficiency
  • spinal cord compression, imminent long bone fracture, or any other condition likely to require radiation therapy and/or steroids for pain control
  • known adrenalcortical insufficiency
  • any medical contraindications to receiving prednisone
  • prior treatment with sipuleucel-T
  • previous treatment with abiraterone acetate (Zytiga(R)) or ipilimumab (Yervoy(TM))
  • a requirement for systemic immunosuppressive therapy for any reason. Use of inhaled, intra-nasal, intra-articular, and topical steroids was allowed.
  • treatment with any investigational vaccine or immunotherapy
  • treatment with any chemotherapy prior to registration.
  • a history of stage III or greater cancer, excluding prostate cancer. Basal or squamous cell skin cancers must have been adequately treated and the subject must be disease-free at the time of registration. Subjects with a history of stage I or II cancer must have been adequately treated and been disease-free for ≥ 3 years at the time of registration.
  • myocardial infarction or ventricular or atrial arrhythmia within 6 months prior to registration
  • ongoing anti-androgen withdrawal response.
  • systemic steroid use within ≤ 60 days of registration
  • treatment with denosumab (Xgeva(R) or Prolia (R)) within ≤ 3 months prior to registration
  • positive test for human immunodeficiency virus (HIV) or human T cell lymphotrophic virus (HTLV) infections. Subjects with a positive test for hepatitis B or hepatitis C were allowed provided they meet the liver function test (LFT) criteria and have no signs of acute infection or active disease.
  • treatment with any of the following medications or interventions within 28 days prior to registration: external beam radiation or major surgery requiring general anesthetic; saw palmetto; megestrol acetate (Megace(R)), diethylstilbestrol, and cyproterone; 5-alpha-reductase inhibitors (e.g. finasteride [Proscar(R)], dutasteride [Avodart(R)]); steroidal anti-androgen therapy; any other systemic therapy for prostate cancer, except for medical castration; treatment with any other investigational product for prostate cancer; substrates of CYP2D6 (e.g. including but not limited to thioridazine); inhibitors of CYP3A4 (e.g. including but not limited to ketoconazole, itraconazole, clarithromycin, nefazodone, telithromycin, and voriconazole); inducers of CYP3A4 (e.g. including but not limited to phenytoin, carbamazepine, rifampin, rifapentine, and phenobarbital)
  • a requirement for treatment with opioid analgesics within 21 days prior to registration
  • an active infection or infection requiring parenteral antibiotic therapy or causing fever within 7 days of registration
  • any medical intervention, or other condition, or any other circumstance that, in the opinion of the Investigator or the Dendreon Medical Monitor, could compromise adherence with study requirements or otherwise compromise the study's objectives
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01487863
P11-3
No
Not Provided
Undecided
Not Provided
Dendreon
Dendreon
Not Provided
Study Director: Robert Israel, MD Valeant Pharmaceuticals North America LLC
Dendreon
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP